ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): David
2. Surname (Last Name): Lederer
3. Date: 09-March-2018

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Fernando Martinez

5. Manuscript Title: Idiopathic Pulmonary Fibrosis

6. Manuscript Identifying Number (if you know it): 17-0575

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☑ Yes ☐ No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Genentech/Roche	☐	☑	☐	☐	Consulting/Advisory Board/Steering cmte related to ILD
Boehringer-Ingelheim	☑	☑	☐	☐	institutional support for clinical trial and advisory board.
Veracyte	☐	☑	☐	☐	consulting/advisory board for ILD.
Degge Group	☐	☑	☐	☐	N.B. Not pharma. This is a pharmacoepidemiology consulting company) Adjudication committee
France Foundation	☐	☑	☐	☐	Steering committee, lecture fees, generation of education content

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Fibrogen	✓	✓			institutional support for clinical trial; consulting.
Global Blood Therapeutics	✓	✓			institutional support for clinical trial; consulting.
Patara		✓			consulting on IPF.
Philips Respironics		✓			consulting on IPF.
Pulmonary Fibrosis Foundation				✓	Columbia University receives fees for consulting services. I have not received fees from PFF in the past 2 years
Immuneworks		✓			consulting on IPF. None in past 2 years
Sanofi Genzyme		✓			consulting on IPF.
Galapagos		✓			consulting on IPF.

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Lederer reports grant support and personal fees from Boehringer-Ingelheim, Fibrogen, and Global Blood Therapeutics, personal fees from Genentech/Roche, Veracyte, Degge Group, France Foundation, Patara, Philips Respironics, Immuneworks, Sanofi Genzyme, and Galapagos, other from the Pulmonary Fibrosis Foundation outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Fernando
2. Surname (Last Name): Martinez
3. Date: 19-March-2018

4. Are you the corresponding author? ☑ Yes ☐ No

5. Manuscript Title: Idiopathic Pulmonary Fibrosis

6. Manuscript Identifying Number (if you know it): 17-05751

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☑ Yes ☐ No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
American College of Chest Physicians	☐	☑	☑	☐	COPD CME programs in India - (honoraria and travel support)
AstraZeneca	☐	☑	☑	☐	COPD Advisory Boards (honoraria and travel support); Study Steering Committee (honoraria and travel support), ALAT presentation (honoraria and travel support)

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Boehringer Ingelheim	☐	☑	☑	☑	COPD Advisory Board (honoraria and travel support) ATS presentation (honoraria); IPF Study Steering Committee (honoraria and travel support), IPF disease state presentation at ALAT (honoraria and travel support), Progressive pulmonary fibrosis DSMB (no financial support)	
ProterrixBio	☐	☐	☐	☑	COPD Scientific Advisory Board (no direct financial compensation, support for NIH study - Proterrix partnered with NHLBI in the Spiromics program at my encouragement)	
Continuing Education	☐	☑	☑	☐	Cough CME program (honoraria and travel support)	
Columbia University	☐	☑	☐	☐	COPD CME program (honoraria)	
ConCert	☐	☑	☑	☐	COPD Advisory Board (honoraria and travel support)	
Genentech	☐	☑	☑	☑	COPD Advisory Board (honoraria and travel support) and asthma DSMB (no support); IPF Advisory Board (honoraria and travel support)	
GlaxoSmithKline	☐	☑	☑	☑	COPD Advisory Boards (honoraria and travel support), Study Steering Committee (travel support), DSMB (academic co-authorship), ERS presentation (travel support)	
Haymarket Communications	☐	☑	☐	☐	COPD CME presentation (honoraria)	
Inova Fairfax Health System	☐	☑	☑	☐	COPD CME presentation (honoarium and travel support)	
Integritas	☐	☑	☐	☐	COPD CME programs (honoraria)	
Inthought Research	☐	☑	☐	☐	COPD/asthma teleconference (honoraria)	
MD Magazine	☐	☑	☑	☐	COPD CME program (honorarium and travel support)	
Methodist Hospital Brooklyn	☐	☑	☐	☐	COPD CME program (honoraria)	
Miller Communicatinos	☐	☑	☑	☐	COPD and IPF CME programs (honoraria and travel support)	
National Association for Continuing Education	☐	☑	☑	☐	COPD and IPF CME programs (honoraria and travel support)	

ICMJE Form for Disclosure of Potential Conflicts of Interest

Novartis	☐	☑	☑	☐	COPD Advisory Board and International meeting COPD disease presentations (honoraria and travel support)
New York University	☐	☑	☐	☐	COPD CME program (honoraria)
Pearl Pharmaceuticals	☐	☑	☑	☐	COPD Advisory Boards (honoraria and travel support)
PeerView Communications	☐	☑	☑	☐	COPD CME programs (honoraria and travel support)
Prime Communications	☐	☑	☑	☐	COPD CME programs (honoraria and travel support)
Puerto Rican Respiratory Society	☐	☑	☑	☐	COPD and IPF CME program (honoraria and travel support)
Chiesi	☐	☑	☑	☐	COPD CME presentation (honoraria and travel support)
Roche	☐	☑	☑	☐	COPD Advisory Board (honoraria and travel support)
Sunovion	☐	☑	☑	☐	COPD Advisory Board (honoraria and travel support)
Theravance	☐	☑	☑	☐	COPD Advisory Board (honoraria and travel support)
Unity	☐	☑	☐	☐	COPD teleconference (honoraria)
UpToDate	☐	☑	☐	☐	COPD CME (honoraria)
WebMD/MedScape	☐	☑	☐	☐	COPD CME presentations (honoraria)
Western Connecticut Health Network	☐	☑	☐	☐	COPD CME presentation (honoraria)
Afferent	☐	☐	☐	☑	IPF Study Steering Committee (co-authorship)
Academic CME	☐	☑	☐	☐	IPF CME programs (personal fee honoraria)
Bayer	☐	☐	☐	☑	IIP PH Study Steering Committee (co-authorship)
Clarion	☐	☑	☐	☐	IPF TC consultation (honoraria)
Gilead	☐	☐	☐	☑	IPF Study Steering Committee (co-authorship)
Nitto	☐	☐	☑	☐	IPF Study Teleconference and Steering Committee (travel support)
Patara	☐	☑	☐	☐	Venture capital expert advice for IPF Study (honoraria)
France Foundation	☐	☑	☐	☐	IPF CME program (honoraria)
PeerView	☐	☑	☐	☐	IPF CME presentation (honoraria)
PlatformIQ	☐	☑	☐	☐	IPF CME program (honoraria)

Potomac	☐	☑	☑	☐	IPF CME presentations (honoraria and travel support)
Stromedix/Biogen	☐	☐	☐	☑	IPF Study DSMB (no support)
University of Alabama Birmingham	☐	☑	☑	☐	IPF CME presentation (honoraria and travel support)
Veracyte	☐	☐	☐	☑	IPF Study Steering Committee (co-authorship)
Zambon	☐	☐	☑	☐	IPF Study Meeting (travel support)
American Thoracic Society	☐	☑	☐	☐	AJRCCM DE (honoraria)
NIH	☑	☐	☐	☐	IPF UO1, COPD UO1/RO1

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Martinez reports personal fees and non-financial support from American College of Chest Physicians, AstraZeneca, Continuing Education, ConCert, Inova Fairfax Health System, MD Magazine, Miller Communicatinos, National Association for Continuing Education, Novartis, Pearl Pharmaceuticals, PeerView Communications, Prime Communications, Puerto Rican Respiratory Society, Chiesi, Roche, Sunovion, Theravance, Potomac, and the University of Alabama Birmingham, personal fees, non-financial support and other from Boehringer Ingelheim, Genentech, and GlaxoSmithKline, other from ProterrixBio, Afferent, Bayer, Gilead, Stromedix/Biogen, and Veracyte, personal fees from Columbia University, Haymarket Communications, Integritas, Inthought Research, Methodist Hospital Brooklyn, New York University, Unity, UpToDate, WebMD/MedScape, Western Connecticut Health Network, Academic CME, Clarion, Patara, France Foundation, PeerView, PlatformIQ, and the American Thoracic Society, non-financial support from Nitto and Zambon, grant support from NIH outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.